Medical Information Only. Always consult your healthcare provider before enrolling in any clinical trial.
NCT00284154 · ClinicalTrials.gov registry record · Phase 2
Vinflunine in the Treatment of Patients With Relapsed Extensive Small Cell Lung Cancer
A Phase 2 study, sponsored by SCRI Development Innovations.
- Completed
- Registry status
- Phase 2
- Development phase
- 51
- Enrollment target
NCT00284154 is a Phase 2 study that has completed, run by SCRI Development Innovations. The registered enrollment target is 51 participants.
The verdict
NCT00284154, a Phase 2 study, has completed, sponsored by SCRI Development Innovations.
- COMPLETED
- Registry status
- Phase 2
- Development phase
- 51 participants
- Enrollment target
Study Summary
This clinical trial involves the administration of the chemotherapeutic medication vinflunine. Vinflunine is not approved by the FDA and is experimental in the treatment of extensive small cell lung cancer. The purpose of this research trial is to study the effectiveness of vinflunine in patients with relapsed extensive small cell lung cancer, evaluate the toxicity, and evaluate how long the response to this drug lasts.
Interventions
- DRUG Vinflunine
Trial Details
| Field | Value |
|---|---|
| Enrollment Target | 51 participants |
| Start Date | 2006-01 |
| Est. Completion | 2009-11 |
| Phase | Phase 2 |
Interested in This Trial?
Full Details on ClinicalTrials.gov ↗What the Registry Record Tells You About NCT00284154
The ClinicalTrials.gov registry entry for NCT00284154 describes a study currently listed as completed, categorized as Phase 2. The registered enrollment target is 51 participants, a figure that helps gauge the scale of data the investigators plan to collect. The listed sponsor is SCRI Development Innovations, which has 146 total studies on file at ClinicalTrials.gov.
The record links to 0 conditions, and to 1 intervention - of which Vinflunine is the first listed.
NCT00284154 reports 0 study locations.
Frequently Asked Questions
What is clinical trial NCT00284154 about?
NCT00284154 is a clinical study titled "Vinflunine in the Treatment of Patients With Relapsed Extensive Small Cell Lung Cancer". This clinical trial involves the administration of the chemotherapeutic medication vinflunine. Vinflunine is not approved by the FDA and is experimental in the treatment of extensive small cell lung cancer. The purpose of this research trial is to study the effectiveness of vinflunine in patients wi...
What is the current status of trial NCT00284154?
This trial is currently completed. It is a Phase 2 study. The enrollment target is 51 participants. The study started on 2006-01. Estimated completion is 2009-11.
What interventions are being tested in trial NCT00284154?
The interventions under investigation include: Vinflunine (DRUG).
Who is sponsoring clinical trial NCT00284154?
This trial is sponsored by SCRI Development Innovations, which has 146 total clinical trials registered on ClinicalTrials.gov.
Learn More About Clinical Trials
Explore more on PlainTrial
Read our methodology - how this data is sourced, computed, and verified.
Related
Every figure on PlainTrial is rendered directly from the ClinicalTrials.gov registry, no number is typed in by an editor. This page mirrors this trial's own ClinicalTrials.gov registry record, live from the dataset. See our editorial standards & corrections policy, the methodology behind these numbers, or report a data error.